Lineage Cell Therapeutics, Inc. (LCTX) Amortization of Intangible Assets USD 2011 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
Summary
Lineage Cell Therapeutics, Inc. quarterly/annual Amortization of Intangible Assets history and growth rate from 2011 to 2024.
  • Lineage Cell Therapeutics, Inc. Amortization of Intangible Assets for the quarter ending March 31, 2024 was $22 K, a 33.3% decline year-over-year.
  • Lineage Cell Therapeutics, Inc. annual Amortization of Intangible Assets for 2023 was $130 K, a 10.3% decline from 2022.
  • Lineage Cell Therapeutics, Inc. annual Amortization of Intangible Assets for 2022 was $145 K, a 31% decline from 2021.
  • Lineage Cell Therapeutics, Inc. annual Amortization of Intangible Assets for 2021 was $210 K, a 82.7% decline from 2020.
Amortization of Intangible Assets, Trailing 12 Months (USD)
Amortization of Intangible Assets, Quarterly (USD)
Amortization of Intangible Assets, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $22 K -$11 K -33.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q1 2023 $33 K +$5 K +17.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q2 2022 $125 K $32 K -$1 K -3.03% Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-11
Q1 2022 $126 K $28 K -$84 K -75% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $210 K $32 K Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 $33 K -$217 K -86.8% Jul 1, 2021 Sep 30, 2021 10-Q 2021-11-10
Q2 2021 $33 K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $112 K -$386 K -77.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q3 2020 $250 K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q1 2020 $498 K +$13 K +2.68% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q1 2019 $2.1 M $485 K -$97 K -16.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $2.19 M $410 K -$137 K -25% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 $2.33 M $600 K $0 0% Jul 1, 2018 Sep 30, 2018 10-Q 2018-11-08
Q2 2018 $2.33 M $600 K $0 0% Apr 1, 2018 Jun 30, 2018 10-Q 2018-08-02
Q1 2018 $2.33 M $582 K -$20 K -3.32% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $2.35 M $547 K Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 $600 K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $600 K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $602 K -$712 K -54.2% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q1 2016 $1.31 M $0 0% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q1 2015 $1.31 M -$54 K -3.95% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q1 2014 $1.37 M +$725 K +113% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-08
Q1 2013 $643 K +$107 K +19.9% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-12
Q1 2012 $536 K +$79.6 K +17.4% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-10
Q1 2011 $456 K Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.